Navigation Links
Obesity and Diabetes Are Increasing in Cats

ST. JOSEPH, Mo., Nov. 10, 2010 /PRNewswire/ -- Diabetes isn’t just a human disease. This November – American Diabetes Month® – pet owners should know that the feline members of their families could suffer from the condition, too.

Type 2 diabetes is the most common form in the United States and occurs in both cats and people. Feline diabetes, a treatable and manageable disease on the rise, affects approximately one in 200 cats nationwide.

"Similar to humans, obesity predisposes cats to diabetes, making diet a major factor in maintaining a cat’s health," says Ruth MacPete, DVM, a San Diego based veterinarian. "Feline diabetes, like most diseases, is easier to treat the earlier it is diagnosed."

Early warning signs include:

  • Increased thirst
  • Sudden increase in appetite
  • Sudden weight loss (despite an increase in appetite)
  • Increased urination
  • Increased lethargy

Most cats with feline diabetes may still maintain an active and healthy lifestyle. Along with appropriate diet and exercise, veterinarians often recommend insulin injections.

"Veterinarians are fortunate enough to now have PROZINC® insulin, the first and only FDA approved long-acting insulin for cats, available to help them effectively regulate their feline diabetic patients,” says MacPete. As with all insulins, cats should be evaluated for pre-existing conditions and currently prescribed medications prior to treatment with PROZINC. Routine monitoring of clinical signs and blood parameters, such as glucose and fructosamine, is essential to maintain a regulated cat.

While November is American Diabetes Month®, pet owners should monitor their cats for symptoms of feline diabetes year-round. The American Association of Feline Practitioners recommends that a veterinarian examine cats at least once a year and twice annually if they are over the age of seven.

For more information about feline diabetes, please visit

For more information about PROZINC, please visit

About Boehringer Ingelheim

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development. For more information, please visit:

SOURCE Boehringer Ingelheim Vetmedica, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Council on Exercise (ACE) Announces Nationwide Effort to Eliminate Obesity in America
2. Results of Two New Clinical Studies Show Promise of Emerging Mobile Health Technology to Combat Obesity Epidemic
3. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
4. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
5. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
6. SIRIUS XMs Doctor Radios The Deans List To Focus On Link Between Early Antibiotic Use In Children And Obesity
7. FierceBiotech Names Obesity Company Gelesis to Fierce 15 List of Top Emerging Biotech Companies
8. Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
11. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)...  Novartis will demonstrate the strength of its research ... Society of Hematology (ASH) Annual Meeting. Presentations will highlight ... supportive care, including key findings in rare and difficult-to-treat ... ASH Annual Meeting will be held December 5-8 in ... Oncology . "We will be presenting encouraging overall survival ...
(Date:11/30/2015)... REHOVOT, Israel , Nov. 30, 2015 ... focused on acquiring and developing innovative therapies for ear, ... of Keith A. Katkin as chairman of ... Flesher , chief executive officer for OticPharma, Ltd.  "Keith ... As chairman, he will be able to share this ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Solutions, announced at the Radiology Society of North America (RSNA) annual meeting, being ... over 60% growth from 2014. Throughout 2015, the company has completed installations ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors ... independent living, assisted living and all other retirement options. Support for issues surrounding ... research remains a top priority. , So it’s no surprise that every ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming Dec. 8 virtual conference ... Health and UCare, MissionPoint Health Partners, and Intel Corp. Leaders from these ...
(Date:11/30/2015)... ... 30, 2015 , ... Vasont Systems, a top component content ... extension unites with Syncro Soft’s latest software update, oXygen XML editor Version 17.1. ... the latest release of oXygen® XML editor and the Vasont® CCMS. , ...
(Date:11/30/2015)... ... November 30, 2015 , ... Scott ... one of a select few plastic surgeons in the New York City area ... SculpSure™ is the world’s first heat-induced laser treatment for fat loss in the ...
Breaking Medicine News(10 mins):